Adiponectin and leptin levels in migraineurs in the atherosclerosis risk in communities study

Neurology

Volumn 83, Issue 24, 2014, Pages 2211-2218

  Dearborn, Jennifer L ^a   Schneider, Andrea L C ^b   Gottesman, Rebecca F ^c   Kurth, Tobias ^d,e   Pankow, James S ^f   Couper, David J ^g   Rose, Kathryn M ^g,h   Williams, Michelle A ⁱ   Peterlin, B Lee ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INSERM   (France)

^e UNIVERSITÉ DE BORDEAUX   (France)

^f UNIVERSITY OF MINNESOTA   (United States)

^g University of North Carolina at Chapel Hill   (United States)

^h SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

ⁱ HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CHOLESTEROL; GLUCOSE; LEPTIN; ADIPOQ PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIET RESTRICTION; ENDOCRINE FUNCTION TEST; FEMALE; FRAIL ELDERLY; HUMAN; HUMAN EXPERIMENT; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIGRAINE; MOLECULAR WEIGHT; NORMAL HUMAN; POPULATION; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; RELIABILITY; SEX DIFFERENCE; BLOOD; BLOOD ANALYSIS; CASE CONTROL STUDY; LONGITUDINAL STUDY; MIGRAINE DISORDERS; ODDS RATIO; PROSPECTIVE STUDY; RISK; STATISTICAL MODEL;

ADIPONECTIN; ATHEROSCLEROSIS; BLOOD CHEMICAL ANALYSIS; CASE-CONTROL STUDIES; FEMALE; HUMANS; LEPTIN; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MIGRAINE DISORDERS; ODDS RATIO; PREVALENCE; PROSPECTIVE STUDIES; RISK; SEX FACTORS; SURVEYS AND QUESTIONNAIRES;

EID: 84925965441     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001067     Document Type: Article

References (38)

1. Chai NC, Scher AI, Moghekar A, Bond DS, Peterlin BL. Obesity and headache: part I: A systematic review of the epidemiology of obesity and headache. Headache 2014;54: 219-234.
2. Scher AI, Terwindt GM, Picavet HS, Verschuren WM, Ferrari MD, Launer LJ. Cardiovascular risk factors and migraine: the GEM population-based study. Neurology 2005;64:614-620.
3. Rainero I, Limone P, Ferrero M, et al. Insulin sensitivity is impaired in patients with migraine. Cephalalgia 2005;25: 593-597.
4. Ward TN. Migraine diagnosis and pathophysiology. Continuum 2012;18:753-763.
5. D'Andrea G, Leon A. Pathogenesis of migraine: from neurotransmitters to neuromodulators and beyond. Neurol Sci 2010;31(suppl 1):S1-S7.
6. Peroutka SJ. Calcitonin gene-related peptide targeted immunotherapy for migraine: progress and challenges in treating headache. BioDrugs 2014;28:237-244.
7. Peterlin BL, Alexander G, Tabby D, Reichenberger E. Oligomerization state-dependent elevations of adiponectin in chronic daily headache. Neurology 2008;70: 1905-1911.
8. Peterlin BL, Tietjen GE, Gower BA, et al. Ictal adiponectin levels in episodic migraineurs: A randomized pilot trial. Headache 2013;53:474-490.
9. Tsao TS, Tomas E, Murrey HE, et al. Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. Different oligomers activate different signal transduction pathways. J Biol Chem 2003;278:50810-50817.
10. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;6:772-783.
11. Peterlin BL, Bigal ME, Tepper SJ, Urakaze M, Sheftell FD, Rapoport AM. Migraine and adiponectin: is there a connection? Cephalalgia 2007;27:435-446.
12. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79-83.
13. Kovacova Z, Tencerova M, Roussel B, et al. The impact of obesity on secretion of adiponectin multimeric isoforms differs in visceral and subcutaneous adipose tissue. Int J Obes 2012;36:1360-1365.
14. Maffei M, Halaas J, Ravussin E, et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995;1:1155-1161.
15. Guldiken B, Guldiken S, Demir M, Turgut N, Tugrul A. Low leptin levels in migraine: A case control study. Headache 2008;48:1103-1107.
16. Bernecker C, Pailer S, Kieslinger P, et al. GLP-2 and leptin are associated with hyperinsulinemia in non-obese female migraineurs. Cephalalgia 2010;30:1366-1374.
17. Peterlin BLRA, Williams MA, Rosenberg JR, et al. Episodic migraine and obesity and the Influence of age, race, and sex. Neurology 2013;81:1314-1321.
18. Bidulescu A, Liu J, Hickson DA, et al. Gender differences in the association of visceral and subcutaneous adiposity with adiponectin in African Americans: the Jackson Heart Study. BMC Cardiovasc Disord 2013;13:9.
19. Isobe T, Saitoh S, Takagi S, et al. Influence of gender, age and renal function on plasma adiponectin level: the Tanno and Sobetsu study. Eur J Endocrinol 2005;153:91-98.
20. ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol 1989;129:687-702.
21. Duncan BB, Schmidt MI, Pankow JS, et al. Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2004;53: 2473-2478.
22. Zhu N, Pankow JS, Ballantyne CM, et al. High-molecularweight adiponectin and the risk of type 2 diabetes in the ARIC Study. J Clin Endocrinol Metab 2010;95:5097-5104.
23. Carson AP, Rose KM, Sanford CP, et al. Lifetime prevalence of migraine and other headaches lasting 4 or more hours: the Atherosclerosis Risk in Communities (ARIC) Study. Headache 2004;44:20-28.
24. Hamedani AG, Rose KM, Peterlin BL, et al. Migraine and white matter hyperintensities: the ARIC MRI study. Neurology 2013;81:1308-1313.
25. Schmidt MI, Duncan BB, Vigo A, et al. Leptin and incident type 2 diabetes: risk or protection? Diabetologia 2006;49:2086-2096.
26. Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): A cohort study. Lancet 1999;353:1649-1652.
27. Cnop M, Havel PJ, Utzschneider KM, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003;46:459-469.
28. Boyne MS, Bennett NR, Cooper RS, et al. Sex-differences in adiponectin levels and body fat distribution: longitudinal observations in Afro-Jamaicans. Diabetes Res Clin Pract 2010;90:e33-e36.
29. Saad MF, Damani S, Gingerich RL, et al. Sexual Dimorphism in plasma leptin Concentration. J Clin Endocrinol Metab 1997;82:579-584.
30. Peake PW, Kriketos AD, Campbell LV, Shen Y, Charlesworth JA. The metabolism of isoforms of human adiponectin: studies in human subjects and in experimental animals. Eur J Endocrinol 2005;153: 409-417.
31. Yarrow JF, Beggs LA, Conover CF, McCoy SC, Beck DT, Borst SE. Influence of Androgens on circulating adiponectin in male and female rodents. PLoS One 2012;7:e47315.
32. Nishizawa H, Shimomura I, Kishida K, et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocytederived protein. Diabetes 2002;51:2734-2741.
33. Xu A, Chan KW, Hoo RLC, et al. Testosterone selectively reduces the high molecular weight form of adiponectin by Inhibiting its secretion from adipocytes. J Biol Chem 2005;280:18073-18080.
34. Obata Y, Yamada Y, Takahi Y, et al. Relationship between serum adiponectin levels and age in healthy subjects and patients with type 2 diabetes. Clin Endocrinol 2013;79: 204-210.
35. Bigal ME, Lipton RB. The epidemiology, burden, and comorbidities of migraine. Neurol Clin 2009;27:321-334.
36. Rozen TD, Swanson JW, Stang PE, McDonnell SK, Rocca WA. Increasing incidence of medically recognized migraine headache in a United States population. Neurology 1999;53:1468-1473.
37. Peterlin BL, Scher AI. Migraine and the social selection vs causation hypotheses: A question larger than either/or? Neurology 2013;81:942-943.
38. Stewart WF, Roy J, Lipton RB. Migraine prevalence, socioeconomic status, and social causation. Neurology 2013;81:948-955.